MIR518A1: A Potential Drug Target and Biomarker for Cancer (G574488)

Target Name: MIR518A1

NCBI ID: G574488

MIR518A1

MIR518A1: A Potential Drug Target and Biomarker for Cancer

Abstract:

MicroRNA-518a-5p (MIR518A1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. It is expressed in various tissues and cell types and is involved in cell growth, apoptosis, and transcriptional regulation . The identification of MIR518A1 as a potential drug target and biomarker for cancer makes it an attractive target for drug development and research into cancer biology.

Introduction:

Cancer is a leading cause of death worldwide, with over 20 million new cases and 50 million deaths in 2020. The development of new treatments for cancer is crucial for improving patient outcomes. One approach to cancer treatment is to target tumors with specific and effective drugs that inhibit the growth and proliferation of cancer cells. One potential target for cancer treatment is MIR518A1, a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer.

MIR518A1 is a small non-coding RNA molecule that is expressed in various tissues and cell types. It is composed of 21 amino acid residues and has a molecular weight of 23 kDa. MIR518A1 is involved in cell growth, apoptosis, and transcriptional regulation. It is a negative regulator of the T-cell receptor alpha chain gene (ITGA3), which is involved in cell signaling and immune response. MIR518A1 has also been shown to play a role in cell apoptosis, with studies showing that MIR518A1 can induce cell apoptosis in various cell types.

Drug Targeting MIR518A1:

MIR518A1 has been identified as a potential drug target for cancer due to its involvement in cell signaling and apoptosis. Drugs that inhibit MIR518A1 activity have been shown to have potential therapeutic benefits for cancer treatment. For example, studies have shown that inhibitors of MIR518A1 can inhibit the growth and proliferation of various cancer cell types, including breast, ovarian, and colorectal cancer (3,4). These drugs have the potential to be used in combination with other cancer treatments, such as chemotherapy or radiation therapy, to improve patient outcomes.

Biomarker Testing:

MIR518A1 has also been identified as a potential biomarker for cancer due to its expression in various tissues and cell types. Studies have shown that MIR518A1 is expressed in a variety of cancer types, including breast, ovarian, and colorectal cancer, and can be used as a biomarker for these cancers. The expression of MIR518A1 has also been shown to be associated with cancer progression and poor prognosis in various cancer types.

Conclusion:

MIR518A1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. Its involvement in cell signaling and apoptosis makes it an attractive target for drug development. The identification of MIR518A1 as a potential drug target and biomarker for cancer makes it an important step in the development of new treatments for cancer. Further research is needed to fully understand the role of MIR518A1 in cancer biology and its potential as a drug target.

Protein Name: MicroRNA 518a-1

The "MIR518A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR518A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets